Immatics (IMTX) Competitors $5.14 -0.26 (-4.81%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. MLTX, IMVT, IBRX, XENE, AMRX, HCM, OGN, MIRM, APLS, and ARWRShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Immatics vs. MoonLake Immunotherapeutics Immunovant ImmunityBio Xenon Pharmaceuticals Amneal Pharmaceuticals HUTCHMED Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Arrowhead Pharmaceuticals Immatics (NASDAQ:IMTX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Which has more volatility and risk, IMTX or MLTX? Immatics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Is IMTX or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Immatics' net margin of -47.94%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Immatics' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-47.94% -15.90% -9.38% MoonLake Immunotherapeutics N/A -15.54%-15.09% Do insiders & institutionals believe in IMTX or MLTX? 64.4% of Immatics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, IMTX or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$144.15M4.33-$104.98M-$0.17-30.24MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-16.71 Does the MarketBeat Community favor IMTX or MLTX? MoonLake Immunotherapeutics received 41 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 82.76% of users gave MoonLake Immunotherapeutics an outperform vote while only 75.61% of users gave Immatics an outperform vote. CompanyUnderperformOutperformImmaticsOutperform Votes3175.61% Underperform Votes1024.39% MoonLake ImmunotherapeuticsOutperform Votes7282.76% Underperform Votes1517.24% Do analysts rate IMTX or MLTX? Immatics presently has a consensus price target of $17.00, suggesting a potential upside of 230.74%. MoonLake Immunotherapeutics has a consensus price target of $78.71, suggesting a potential upside of 104.85%. Given Immatics' stronger consensus rating and higher probable upside, equities analysts plainly believe Immatics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IMTX or MLTX? In the previous week, MoonLake Immunotherapeutics had 14 more articles in the media than Immatics. MarketBeat recorded 26 mentions for MoonLake Immunotherapeutics and 12 mentions for Immatics. Immatics' average media sentiment score of 1.44 beat MoonLake Immunotherapeutics' score of 1.11 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMoonLake Immunotherapeutics beats Immatics on 10 of the 18 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$621.73M$2.93B$5.38B$8.39BDividend YieldN/A1.71%5.21%4.10%P/E Ratio-7.7530.5026.7619.71Price / Sales4.33400.15389.71117.54Price / CashN/A168.6838.2534.62Price / Book1.783.286.784.50Net Income-$104.98M-$72.17M$3.23B$248.18M7 Day Performance9.59%2.96%1.51%0.23%1 Month Performance18.98%3.25%10.03%12.39%1 Year Performance-50.29%-28.29%16.65%7.07% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.8235 of 5 stars$5.14-4.8%$17.00+230.7%-51.8%$621.73M$144.15M-7.75260News CoveragePositive NewsMLTXMoonLake Immunotherapeutics3.2861 of 5 stars$39.20+4.2%$78.71+100.8%-1.3%$2.51BN/A-30.392Positive NewsAnalyst UpgradeGap UpIMVTImmunovant2.7008 of 5 stars$14.70+1.7%$38.33+160.8%-52.4%$2.50BN/A-5.61120Positive NewsGap UpIBRXImmunityBio1.8548 of 5 stars$2.80-1.4%$12.19+335.3%-61.1%$2.47B$31.22M-3.04590Analyst UpgradeXENEXenon Pharmaceuticals3.2369 of 5 stars$30.95+2.2%$54.82+77.1%-21.9%$2.37B$7.50M-10.98210Analyst DowngradeAMRXAmneal Pharmaceuticals3.252 of 5 stars$7.50-1.3%$11.50+53.3%+8.7%$2.35B$2.83B-11.037,600HCMHUTCHMED2.2729 of 5 stars$13.48+0.7%$19.00+40.9%-33.6%$2.35B$630.20M0.001,760Positive NewsGap DownOGNOrganon & Co.4.7537 of 5 stars$9.00-0.4%$18.00+100.0%-61.3%$2.34B$6.29B2.7010,000MIRMMirum Pharmaceuticals4.0851 of 5 stars$44.89-0.3%$60.73+35.3%+71.8%$2.22B$379.25M-22.22140News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.175 of 5 stars$17.67+1.3%$40.42+128.8%-59.1%$2.22B$775.84M-8.70770ARWRArrowhead Pharmaceuticals3.5175 of 5 stars$15.74+0.2%$42.13+167.6%-38.8%$2.17B$545.21M-3.04400News CoverageAnalyst Forecast Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Immunovant Competitors ImmunityBio Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors HUTCHMED Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMTX Stock Free IMTX Stock Alerts